Kabe Katie L, Kolesar Jill M
School of Pharmacy, University of Wisconsin, Madison, WI 53719, USA.
Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. doi: 10.2146/ajhp050400.
The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor-2 (HER2). Currently, trastuzumab is indicated for use in HER2-positive patients with metastatic breast cancer. Because trastuzumab specifically targets a receptor that is overexpressed in tumor cells, it is less likely to cause the cytotoxic adverse effects of traditional chemotherapy. Cardiotoxicity has been a major concern, however. Several trials were started to evaluate trastuzumab in the adjuvant setting in patients diagnosed with early-stage breast cancer. The interim results of these trials have shown a promising effect of adjuvant therapy with trastuzumab in improving overall survival, disease-free survival, relapse-free survival, and distant-disease-free survival.
The use of trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer can lead to increased survival. The appropriateness of trastuzumab therapy should be considered based on HER2 status, cost, and risk of toxicity.
探讨曲妥珠单抗在局部浸润性乳腺癌辅助治疗中的作用。
曲妥珠单抗是一种人源化单克隆抗体，可与人表皮生长因子受体2（HER2）的细胞外结构域结合。目前，曲妥珠单抗被批准用于HER2阳性转移性乳腺癌患者。由于曲妥珠单抗特异性靶向肿瘤细胞中过度表达的受体，它不太可能引起传统化疗的细胞毒性不良反应。然而，心脏毒性一直是一个主要问题。开展了多项试验以评估曲妥珠单抗在早期乳腺癌患者辅助治疗中的效果。这些试验的中期结果显示，曲妥珠单抗辅助治疗在改善总生存期、无病生存期、无复发生存期和无远处疾病生存期方面具有显著效果。
在HER2阳性乳腺癌患者中使用曲妥珠单抗作为辅助治疗可提高生存率。应根据HER2状态、成本和毒性风险来考虑曲妥珠单抗治疗的适用性。
